Republic Healthcare Limited (8357) AI Stock Analysis

• Market Cap: HK$95.47M
• Dividend Yield: N/A
• Average Volume (3M): 88.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: -11.68%
• EPS Growth: -71.01%
• Country: HK
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.01
• Shares Outstanding: 624,000,000
• 10 Day Avg. Volume: 151,000
• 30 Day Avg. Volume: 88,166
• PEG Ratio: 0.49
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 0.75
• P/FCF Ratio: 134.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: HK$0.00 ▼(-100.00% Downside)

The overall stock score is primarily influenced by financial performance, which shows strong equity positions but is hindered by declining revenues and net losses. Technical analysis indicates a bearish trend with potential oversold conditions, while valuation is poor due to negative earnings and lack of dividends.

Republic Healthcare Limited Business Overview & Revenue Model

Company Description

Republic Healthcare Limited (8357) is a healthcare company specializing in the provision of a wide range of medical and healthcare services. With a focus on enhancing patient care, the company operates across various sectors, including hospital management, outpatient services, and specialty clinics. Republic Healthcare is committed to leveraging innovative technologies and best practices to improve health outcomes and operational efficiencies, offering core services such as diagnostic imaging, rehabilitation, and preventive care.

How the Company Makes Money

Republic Healthcare Limited generates revenue through multiple streams, primarily from its healthcare services offered in hospitals and clinics. The company earns money by charging patients for medical consultations, treatments, and procedures. Additionally, Republic Healthcare collaborates with insurance providers, receiving reimbursements for services rendered to insured patients. Another key revenue stream includes partnerships with pharmaceutical companies for clinical trials and research, where the company may receive funding for conducting studies. Furthermore, the company may generate income from the sale of medical supplies and equipment within its facilities, contributing to its overall revenue.

Republic Healthcare Limited Financial Statement Overview

Summary

Republic Healthcare Limited demonstrates strong equity positions with low leverage, which provides financial stability. However, declining revenues and persistent net losses pose significant challenges. Operational improvements are visible, but sustained profitability remains a concern.

Income Statement

Revenue has declined over the past three years, with a negative revenue growth rate and shrinking gross profit margin from 72.1% in 2019 to 24.4% in 2024. The net profit margin is negative, indicating losses. However, the company improved its EBIT margin from negative to 18.42% in 2024, showing some operational efficiency.

Balance Sheet

The company maintains a strong equity position with an equity ratio consistently above 80%. Debt-to-equity ratio is low at 0.068, indicating low financial leverage. However, the return on equity is negative due to net losses, which presents a challenge for profitability.

Cash Flow

The free cash flow has fluctuated, with a decline in free cash flow growth rate in recent periods. The operating cash flow to net income ratio is positive, indicating operational cash generation despite accounting losses. However, the free cash flow to net income ratio is inconsistent, reflecting variability in capital management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.51M	9.23M	10.28M	9.44M	13.97M	13.89M
Gross Profit	1.67M	6.48M	2.70M	5.97M	9.13M	9.83M
EBITDA	-1.30M	-188.79K	29.34K	-387.88K	962.89K	1.43M
Net Income	-1.25M	-178.16K	-855.12K	-1.48M	-997.93K	-143.61K
Balance Sheet
Total Assets	13.65M	14.48M	15.64M	16.42M	19.27M	19.34M
Cash, Cash Equivalents and Short-Term Investments	9.75M	11.52M	11.93M	11.83M	14.27M	13.07M
Total Debt	1.25M	858.22K	961.16K	810.47K	1.55M	2.76M
Total Liabilities	2.34M	1.93M	2.89M	2.30M	3.67M	6.09M
Stockholders Equity	11.31M	12.55M	12.75M	14.12M	15.59M	13.05M
Cash Flow
Free Cash Flow	-1.22M	51.27K	806.24K	-1.16M	-1.13M	232.36K
Operating Cash Flow	-1.15M	125.07K	899.91K	-734.46K	-510.07K	771.30K
Investing Cash Flow	1.24M	-93.94K	831.49K	-987.23K	-1.56M	7.62M
Financing Cash Flow	-560.42K	-531.65K	-587.62K	-689.73K	2.28M	-1.36M

Republic Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8357, the sentiment is Positive. The current price of 0.15 is below the 20-day moving average (MA) of 0.15, below the 50-day MA of 0.15, and above the 200-day MA of 0.11, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.09 is Neutral, neither overbought nor oversold. The STOCH value of 44.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8357.

Republic Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2293	75 Outperform	HK$229.40M	13.01	7.84%	4.39%	-21.50%	-43.12%
8161	59 Neutral	HK$32.45M	3.04	105.83%	―	-8.48%	―
8357	56 Neutral	HK$95.47M	―	-10.31%	―	-11.68%	-71.01%
8307	56 Neutral	HK$76.97M	―	-44.60%	―	-8.20%	-10.39%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8143	51 Neutral	HK$192.77M	―	―	―	-58.63%	40.85%
8437	43 Neutral	HK$9.46M	―	―	―	14.64%	-81.95%